$5.520
-0.040 (-0.72%)Zum Schluss
TVGN im Vergleich zur Peergroup
In the context of the broader market, TVGN competes directly with industry leaders such as SCYX and VERU. With a market capitalization of $35.94M, it holds a significant position in the sector. When comparing efficiency, TVGN's gross margin of N/A stands against SCYX's N/A and VERU's N/A. Such benchmarking helps identify whether Tevogen Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Tevogen Bio Holdings Inc
Tevogen Bio Holdings has shown poor financial performance, with total revenue of $396,586 in Q1 2025 but zero revenue in subsequent quarters. The net income has been consistently negative, with the latest figure at -$5,839,776 for Q2 2026. The company has a current ratio of 0.33, indicating potential liquidity issues.
Financials
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.